Cholinesterase inhibitors and memory

Chemico-Biological Interactions

Volumn 187, Issue 1-3, 2010, Pages 403-408

  Pepeu, Giancarlo ^a   Giovannini, Maria Grazia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholine; Alzheimer's Disease; Brain cholinergic system; Cognitive processes

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; SCOPOLAMINE; TACRINE;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; AMNESIA; ARTICLE; ATTENTION; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; EXPLICIT MEMORY; FOREBRAIN; HUMAN; INFORMATION RETRIEVAL; LONG TERM MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; MICRODIALYSIS; NONHUMAN; PERCEPTION; SENSORIMOTOR FUNCTION; SINGLE DRUG DOSE; SPATIAL MEMORY; WORKING MEMORY;

ANIMALIA;

EID: 77955514184     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.11.018     Document Type: Article

References (70)

1. Giacobini E. Cholinesterase in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. The Brain Cholinergic System in Health and Disease 2006, 235-265. Informa Healthcare, Abingdon. E. Giacobini, G. Pepeu (Eds.).
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 2006, CD005593.
3. Lanctot K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., Einarson T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003, 169:557-564.
4. Raschetti R., Maggini M., Sorrentino G.C., Martini N., Caffari B., Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur. J. Clin. Pharmacol. 2005, 61:361-368.
5. Persson C.M., Wallin A.K., Levander S., Minthon L. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol. 2009, 9:7.
6. Pepeu G., Giovannini M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res. 2009, 6:86-96.
7. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
8. Davies P., Maloney A.J.R. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403-1405.
9. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
10. Perry E.K., Johnson M., Kerwin J.M., Piggott M.A., Court J.A., Shaw P.J., Ince P.G., Brown A., Perry R.H. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol. Aging 1992, 13:393-400.
11. Drachman D.A., Leavitt J. Human memory and the cholinergic system: a relationship to aging?. Arch. Neurol. 1974, 30:113-121.
12. Davis K.L., Hollister L.E., Overall J., Johnson A., Train K. Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology (Berl) 1976, 51:23-27.
13. Balota P.A., Dolan P.O., Duchek J.M. Memory changes in healthy older adult. The Oxford Handbook of Memory 2000, 395-409. Oxford University Press, Oxford. E. Tulving, G.I.M. Craik (Eds.).
14. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's Disease. CNS Drugs 1999, 12:307-323.
15. Pepeu G. Preclinical pharmacology of cholinesterase inhibitors. Cholinesterases and Cholinesterase Inhibitors 2000, 145-155. Martin Dunitz, London. E. Giacobini (Ed.).
16. Scali C., Giovannini M.G., Bartolini L., Prosperi C., Hinz V., Schmidt B.H., Pepeu G. Effect of metrifonate on extracellular brain acetylcholine levels and object recognition in aged rats. Eur. J. Pharmacol. 1997, 325:173-180.
17. Giovannini M.G., Scali C., Bartolini L., Schmidt B.H., Pepeu G. Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F334 rats. Eur. J. Pharmacol. 1998, 354:17-24.
18. Jakisch R., Forster S., Kemmerer M., Rothmaler A.K., Ehret A., Zenter J., Feuerstein T.J. Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex. J. Alzheimer's Dis. 2009, 16:635-647.
19. Nordberg A., Darreh-Shori T., Peskind E., Soininen H., Mousavi M., Eagle G., Lane R. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr. Alzheimer Res. 2009, 6:4-14.
20. Venneri A. Imaging treatment effects in Alzheimer's disease. Magn. Reson. Imaging 2007, 25:953-968.
21. Kaasinen V., Nagren K., Jarvenpaa T., Roivainen A., Yu M., Oikonen V., Kurki T., Rinne J.O. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 2002, 22:615-620.
22. Pepeu G., Giovannini M.G. The role of cholinergic system in cognitive processes. Brain Cholinergic Mechanisms 2006, 221-233. Tailor & Francis, Oxford. E. Giacobini, G. Pepeu (Eds.).
23. Pepeu G., Giovannini M.G. Changes in acetylcholine extracellular levels during cognitive processes. Learn. Mem. 2004, 11:21-27.
24. Pepeu G., Giovannini M.G. Acetylcholine: I Muscarinic receptors. From Messengers to Molecules: Memories Are Made of These 2004, 90-112. Plenum Press, New York. G. Riedel, D. Platter (Eds.).
25. Giovannini M.G., Rakovska A., Benton R.S., Pazzagli M., Bianchi L., Pepeu G. Effects of novelty and habituation on acetylcholine, GABA, and glutamate release from the frontal cortex and hippocampus of freely moving rats. Neuroscience 2001, 106:43-53.
26. Inglis F.M, Fibiger H.C. Increases in hippocampal and frontal cortical acetylcholine release associated with presentation of sensory stimuli. Neuroscience 1995, 66:81-86.
27. Acquas E., Wilson C., Fibiger H.C. Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. J. Neurosci. 1996, 16:3089-3096.
28. Giovannini M.G, Bartolini L., Kopf S.R., Pepeu G. Acetylcholine release from the frontal cortex during exploratory activity. Brain Res. 1998, 784:218-227.
29. Miranda M.I., Ramirez-Lugo L., Bermudez-Rattoni F. Cortical cholinergic activity is related to the novelty of the stimulus. Brain Res. 2000, 882:230-235.
30. Fournier G.N., Semba K., Rasmusson D.D. Modality- and region-specific acetylcholine release in the rat neocortex. Neuroscience 2004, 126:257-262.
31. Orsetti M., Casamenti F., Pepeu G. Enhanced acetylcholine release in the hippocampus and cortex during acquisition of an operant behavior. Brain Res. 1996, 724:89-96.
32. Giovannini M.G., Pazzagli M., Malmberg-Aiello P., Della C.L., Rakovska A.D., Cerbai F., Casamenti F., Pepeu G. Inhibition of acetylcholine-induced activation of extracellular regulated protein kinase prevents the encoding of an inhibitory avoidance response in the rat. Neuroscience 2005, 136:15-32.
33. Himmelheber A.M., Sarter M., Bruno J.P. Increases in cortical acetylcholine release during sustained attention performance in rats. Brain Res. Cogn. Brain Res. 2000, 9:313-325.
34. Kozak R., Bruno J.P., Sarter M. Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb. Cortex 2006, 16:9-17.
35. Inglis F.M., Day J.C., Fibiger H.C. Enhanced acetylcholine release in hippocampus and cortex during the anticipation and consumption of a palatable meal. Neuroscience 1994, 62:1049-1056.
36. Parikh V., Kozak R., Martinez V., Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron 2007, 56:141-154.
37. Ragozzino M.E., Pal S.N., Unick K., Stefani M.R., Gold P.E. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. J. Neurosci. 1998, 18:1595-1601.
38. Brazhnik E.S., Muller R.U., Fox S.E. Muscarinic blockade slows and degrades the location-specific firing of hippocampal pyramidal cells. J. Neurosci. 2003, 23:611-621.
39. Bartolini L., Risaliti R., Pepeu G. Effect of scopolamine and nootropic drugs on rewarded alternation in a T-maze. Pharmacol. Biochem. Behav. 1992, 43:1161-1164.
40. Anzalone S., Roland J., Vogt B., Savage L. Acetylcholine efflux from retrosplenial areas and hippocampal sectors during maze exploration. Behav. Brain Res. 2009, 201:272-278.
41. Hironaka N., Tanaka K., Izaki Y., Hori K., Nomura M. Memory-related acetylcholine efflux from rat prefrontal cortex and hippocampus: a microdialysis study. Brain Res. 2001, 901:143-150.
42. Fadda F., Cocco S., Stancampiano R. Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats. NeuroReport 2000, 11:2265-2269.
43. Ragozzino M.E., Mohler E.G., Prior M., Palencia C.A., Rozman S. Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol. Learn. Mem. 2009, 91:13-22.
44. McIntyre C.K., Pal S.N., Marriott L.K., Gold P.E. Competition between memory systems: acetylcholine release in the hippocampus correlates negatively with good performance on an amygdala-dependent task. J. Neurosci. 2002, 22:1171-1176.
45. Hasselmo M.E., McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog. Brain Res. 2004, 145:207-231.
46. Celesia G.G., Jasper H.H. Acetylcholine released from cerebral cortex in relation to state of activation. Neurology 1966, 16:1053-1063.
47. Gais S., Born J. Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation. Proc. Natl. Acad. Sci. USA 2004, 101:2140-2144.
48. Rogers J.L., Kesner R.P. Cholinergic modulation of the hippocampus during encoding and retrieval. Neurobiol. Learn. Mem. 2003, 80:332-342.
49. Lanni C., Lenzken S.C., Pascale A., Del V., Racchi I.M., Pistoia F., Govoni S. Cognition enhancers between treating and doping the mind. Pharmacol. Res. 2008, 57:196-213.
50. Davis K.L., Mohs R.C., Tinklenberg J.R., Pfefferbaum A., Hollister L.E., Kopell B.S. Physostigmine: improvement of long-term memory process in normal humans. Science 1978, 201:272-274.
51. Wetherell A. Effects of physostigmine on stimulus encoding in a memory-scanning task. Psychopharmacology (Berl) 1992, 109:198-202.
52. Furey M.L., Pietrini P., Haxby J.V. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000, 290:2315-2319.
53. Bentley P., Vuilleumier P., Thiel C.M., Driver J., Dolan R.J. Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. Neuroimage 2003, 20:58-70.
54. Kukolja J., Thiel C.M., Fink G.R. Cholinergic stimulation enhances neural activity associated with encoding but reduces neural activity associated with retrieval in humans. J. Neurosci. 2009, 29:8119-8128.
55. Hutchison C.W., Nathan P.J., Mrazek L., Stough C. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl) 2001, 155:440-442.
56. Mumenthaler M.S., Yesavage J.A., Taylor J.L., O'Hara R., Friedman L., Lee H., Kraemer H.C. Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 2003, 28:1366-1373.
57. Gron G, Kirstein M., Thielscher A., Riepe M.W., Spitzer M. Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology (Berl) 2005, 182:170-179.
58. Zaninotto A.L., Bueno O.F., Pradella-Hallinan M., Tufik S., Rusted J., Stough C., Pompeia S. Acute cognitive effects of donepezil in young, healthy volunteers. Hum. Psychopharmacol. 2009, 24:453-464.
59. Lemstra A.W., Kalisvaart K.J., Vreeswijk R., van Gool W.A., Eikelenboom P. Pre-operative inflammatory markers and the risk of postoperative delirium in elderly patients. Int. J. Geriatr. Psychiatry 2008, 23:943-948.
60. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Koeppe R.A., Meltzer C.C., Constantine G., Davis J.G., Mathis C.A., DeKosky S.T., Moore R.Y. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:315-319.
61. Hanyu H., Asano T., Sakurai H., Tanaka Y., Takasaki M., Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am. J. Neuroradiol. 2002, 23:27-32.
62. Kanetaka H., Hanyu H., Hirao K., Shimizu S., Sato T., Akai T., Iwamoto T., Koizumi K. Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion. Nucl. Med. Commun. 2008, 29:568-573.
63. Sarter M., Bruno J.P., Turchi J. Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann. NY Acad. Sci. 1999, 877:368-382.
64. Rodda J., Morgan S., Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr. 2009, 21:813-824.
65. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull. 1987, 13:643-668.
66. Ballmaier M., Casamenti F., Scali C., Mazzoncini R., Zoli M., Pepeu G., Spano P.F. Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 2002, 114:91-98.
67. Rodda J., Walker Z. Ten years of cholinesterase inhibitors. Int. J. Geriatr. Psychiatry 2009, 24:437-442.
68. Frankfort S.V., Appels B.A., de Boer A., Tulner L.R., van Campen J.P., Koks C.H., Beijnen J.H., Schmand B.A. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiol. Drug Saf. 2007, 16:545-551.
69. Hardy J., Adolfsson J., Alafuzoff I., Marcusson J., Nyberg P., Perdahl E., Wester P., Winblad B. Transmitter deficits in Alzheimer's disease. Neurochem. Int. 1985, 7:345-363.
70. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:167-179.